Technical Analysis for RNAC - Cartesian Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.19% | |
| Overbought Stochastic | Strength | 0.19% | |
| Slingshot Bullish | Bullish Swing Setup | -9.67% | |
| Parabolic Rise | Strength | -9.67% | |
| Upper Bollinger Band Walk | Strength | -9.67% | |
| Wide Bands | Range Expansion | -9.67% | |
| Overbought Stochastic | Strength | -9.67% |
| Alert | Time |
|---|---|
| Up 1% | about 17 hours ago |
| Possible NR7 | about 18 hours ago |
| 60 Minute Opening Range Breakout | about 21 hours ago |
| Down 2 % | about 22 hours ago |
| Down 1% | about 22 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/02/2024
Cartesian Therapeutics is a clinical-stage company pioneering RNA cell therapies for the treatment of autoimmune diseases. The company’s lead asset, Descartes-08, is a potential first-in-class, RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase 2b clinical development for patients with generalized myasthenia gravis, with additional Phase 2 studies planned in systemic lupus erythematosus as well as ocular autoimmune and vasculitic autoimmune basket trials. Cartesian operates a wholly owned, state-of-the-art cGMP manufacturing facility in Gaithersburg, MD.
Sector: Healthcare
Industry: Biotechnology
Keywords: Autoimmune Disease Cell Therapy Autoimmunity Lupus Myasthenia Gravis Sjögren Syndrome Systemic Lupus Erythematosus Therapies For The Treatment Of Autoimmune Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Autoimmune Disease Cell Therapy Autoimmunity Lupus Myasthenia Gravis Sjögren Syndrome Systemic Lupus Erythematosus Therapies For The Treatment Of Autoimmune Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 42.6 |
| 52 Week Low | 11.665 |
| Average Volume | 75,081 |
| 200-Day Moving Average | 26.58 |
| 50-Day Moving Average | 19.49 |
| 20-Day Moving Average | 20.97 |
| 10-Day Moving Average | 23.09 |
| Average True Range | 2.13 |
| RSI (14) | 65.52 |
| ADX | 36.66 |
| +DI | 31.73 |
| -DI | 16.18 |
| Chandelier Exit (Long, 3 ATRs) | 20.91 |
| Chandelier Exit (Short, 3 ATRs) | 18.90 |
| Upper Bollinger Bands | 26.02 |
| Lower Bollinger Band | 15.91 |
| Percent B (%b) | 0.73 |
| BandWidth | 48.25 |
| MACD Line | 1.57 |
| MACD Signal Line | 1.16 |
| MACD Histogram | 0.4119 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 24.75 | ||||
| Resistance 3 (R3) | 24.67 | 24.09 | 24.50 | ||
| Resistance 2 (R2) | 24.09 | 23.71 | 24.13 | 24.42 | |
| Resistance 1 (R1) | 23.67 | 23.47 | 23.88 | 23.75 | 24.33 |
| Pivot Point | 23.09 | 23.09 | 23.20 | 23.13 | 23.09 |
| Support 1 (S1) | 22.67 | 22.71 | 22.88 | 22.75 | 22.17 |
| Support 2 (S2) | 22.09 | 22.47 | 22.13 | 22.08 | |
| Support 3 (S3) | 21.67 | 22.09 | 22.00 | ||
| Support 4 (S4) | 21.75 |
